证券代码：833266 证券简称：生物谷 公告编号：2023-075 云南生物谷药业股份有限公司 关于控股股东、实际控制人收到北京证券交 易所自律监管措施决定书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、基本情况 相关文书的全称：《关于对深圳市金沙江投资有限公司、林艳和 采取自律监管措施的决定》 北证监管执行函〔2023〕13 号 生效日期：2023 年 9 月 5 日 作出主体：北京证券交易所监管执行部 措施类别：自律监管措施 （涉嫌）违法违规主体及任职情况： | 姓名/名称 | 类别 | 具体任职/关联关系 | | --- | --- | --- | | 深圳市金沙江投资有 | 控股股东 | 控股股东 | | 限公司 | | | | 林艳和 | 实际控制人 | 实际控制人 | 涉嫌违法违规事项类别： 未能履行增持承诺 二、主要内容 （一）涉嫌违法违规事实： 收到日期：2023 年 9 月 6 日 根据公开发行相关主体作出的承诺，以及云南生物谷药业股份有 限公司（以下简称"公司"或"生 ...

（1） 公司回购公司股票 证券代码：833266 证券简称：生物谷 公告编号：2023-072 云南生物谷药业股份有限公司 关于触发稳定股价措施启动条件的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 为维护云南生物谷药业股份有限公司（以下简称"公司"）上市 后股价的稳定，保护投资者的利益，公司制定了稳定股价预案。该预 案已分别经本公司第三届董事会第十一次会议以及 2020 年第二次临 时股东大会审议通过，并已在公开发行说明书中披露。 一、 稳定股价措施的启动条件 公司精选层挂牌后三年内，如公司股票收盘价格连续 20 个交 易日均低于最近一期经审计的每股净资产（每股净资产是指经审计 的公司最近一期合并财务报表中归属于母公司普通股股东权益合 计数除以该期审计基准日时公司的股份总数；最近一期审计基准日 后，因利润分配、资本公积金转增股本、增发、配股等情况导致公 司净资产或股份总数出现变化的，每股净资产应相应进行调整）（以 下简称"启动条件"），且同时满足监管机构对于增持或回购公司 股份等行为的规 ...

证券代码：833266 证券简称：生物谷 公告编号：2023-069 云南生物谷药业股份有限公司 第四届监事会第十一次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本次会议符合《中华人民共和国公司法》及有关法律、法规和《公 司章程》等规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 全体监事以通讯方式参与表决。 1.会议召开时间：2023 年 8 月 11 日 2.会议召开地点：网络 3.会议召开方式：通讯 4.发出监事会会议通知的时间和方式：2023 年 8 月 1 日 以通讯方式 发出 5.会议主持人：监事会主席喻腊梅女士 6.召开情况合法、合规、合章程性说明： 二、议案审议情况 （一）审议通过《2023 年半年度报告及摘要》议案 1.议案内容： 具体内容详见于公司 2023 年 8 月 14 日在北京证券交易所官 网（http://www.bse.cn/）披露的公告《生物谷：2023 年半年度报 告》（公告 ...

证券代码：833266 证券简称：生物谷 公告编号：2023-068 云南生物谷药业股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 8 月 11 日 2.会议召开地点：网络 3.会议召开方式：通讯 4.发出董事会会议通知的时间和方式：2023 年 8 月 1 日以通讯 方式发出 5.会议主持人：董事长徐天水先生 6.会议列席人员：喻腊梅、蔡泽秋、武珊、赖小飞、李驰、张传 开、杜江、李晓燕、陈颖 7.召开情况合法、合规、合章程性说明： 第四届董事会第十九次会议决议公告 二、议案审议情况 （一）审议通过《2023 年半年度报告及摘要的议案》 1.议案内容： 具体内容详见于公司 2023 年 8 月 14 日在北京证券交易所官 网（http://www.bse.cn/）披露的公告《生物谷：2023 年半年度报 告》（公告编号：2023-070）和《生物谷：2023 年半年度报告摘要》 （公告编号：2023-071）。 2 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 313,024,476.75, representing a 10.81% increase compared to CNY 282,475,007.03 in the same period last year[28]. - The gross profit margin improved to 80.68% from 79.80% year-on-year[28]. - The net profit attributable to shareholders of the listed company was a loss of CNY 3,986,917.50, a decrease of 168.50% compared to a profit of CNY 5,819,951.94 in the previous year[28]. - The total revenue for the current period reached ¥313,024,476.75, representing a 10.81% increase compared to ¥282,475,007.03 in the previous year[55]. - Operating revenue grew by 10.81%, up from a mere 0.37% growth in the previous year[32]. - The net profit decreased by 168.50%, worsening from a decline of 77.43% in the same period last year[32]. - The total profit decreased by 154.66% to -¥4,302,607.26, mainly due to increased bad debt provisions[58]. - The comprehensive income total for the first half of 2023 was CNY -3,986,917.50, down from CNY 5,819,951.94 in the same period of 2022[142]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,251,116,161.71, a slight increase of 0.53% from CNY 1,244,512,394.43 at the end of the previous year[30]. - The total liabilities increased by 4.54% to CNY 243,666,077.51 from CNY 233,075,392.73 year-on-year[30]. - The company's debt-to-asset ratio (consolidated) was 19.48%, up from 18.73% in the previous year[30]. - Cash and cash equivalents increased by 5.54% to ¥116,943,697.12, up from ¥110,805,146.17 at the end of the previous period[52]. - The company's short-term borrowings remained stable at ¥78,750,000.00, with a minimal change in percentage from 6.33% to 6.29% of total assets[52]. - Trade receivables decreased by 12.51% to ¥157,430,233.74, down from ¥179,940,912.60 in the previous year[52]. - The total assets as of June 30, 2023, amounted to ¥1,061,429,541.40, a decrease from ¥1,076,910,303.53 at the end of 2022[138]. - Total liabilities as of June 30, 2023, were ¥58,609,275.39, down from ¥64,756,195.59 at the end of 2022[138]. Cash Flow - The net cash flow from operating activities increased to ¥84,171,425.07, a significant improvement of 166.21% compared to the previous year's loss of ¥127,133,552.01[31]. - Operating cash inflow for the first half of 2023 was CNY 411,349,302.57, an increase of 23.5% compared to CNY 333,317,861.49 in the same period of 2022[146]. - Cash outflow from investing activities increased to CNY 98,966,100.95, up from CNY 51,301,347.97 in the previous year, resulting in a net cash outflow of CNY 66,808,994.89[147]. - Cash flow from financing activities showed a net outflow of CNY 11,223,879.23, compared to a net outflow of CNY 3,431,444.59 in the same period last year[147]. Research and Development - R&D expenses surged by 125.82% to ¥9,392,894.55, attributed to increased outsourced R&D projects[58]. - Ongoing research projects include clinical studies on the efficacy of existing products in treating acute ischemic stroke and cardiovascular diseases[44]. - Research and development expenses increased to CNY 9,284,693.53 from CNY 4,159,491.34, reflecting a focus on innovation and product development[143]. Market and Strategy - The company aims to continue expanding its market presence and product offerings, focusing on traditional Chinese medicine and related health products[22]. - The company plans to enhance its marketing strategy by focusing on key markets and integrating weaker markets to boost sales[44]. - The company is actively embracing transformation and innovation in response to favorable policies for the traditional Chinese medicine industry, aiming for high-quality development[49]. Legal and Compliance - The company has ongoing litigation involving a claim of 273.11 million yuan, which represents 27.11% of the net assets as of the reporting period[85]. - The company has initiated civil litigation against Jinsha River and Lin Yanhe, with the Shenzhen Intermediate People's Court accepting the case on August 17, 2022[89]. - The company plans to pursue legal actions to recover the occupied funds, statutory interest, and penalties[88]. Shareholder and Governance - The total number of ordinary shares outstanding is 128 million, with 75.26% being unrestricted shares[112]. - The actual controller and major shareholders have delayed their stock purchase commitments, with a new deadline set for July 31, 2023, to stabilize the company's stock price[107]. - The company has a diverse board composition, including independent directors and female representation[120]. - The company has established a clear structure for its management and supervisory roles to enhance operational efficiency[120]. Environmental and Social Responsibility - The company adheres to environmental protection regulations and has implemented effective management of hazardous waste, ensuring compliance with national standards[76]. - The company has promoted the planting of medicinal herbs in over 10,000 acres, contributing to rural revitalization and improving local farmers' income[74].

本次年度报告业绩说明会将采用网络的方式举行，投资者可登陆 全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年度 报告业绩说明会。 2022 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：833266 证券简称：生物谷 公告编号：2023-050 云南生物谷药业股份有限公司 一、 说明会类型 云南生物谷药业股份有限公司（以下简称"公司"）于 2023 年 4 月 26 日 在 北 京 证 券 交 易 所 指 定 信 息 披 露 平 台 （http://www.bse.cn/）披露了《生物谷：2022 年年度报告》（公告 编号：2023-023）及《生物谷：2022 年年度报告摘要》（公告编号： 2023-025），为方便广大投资者更深入了解公司 2022 年经营业绩的 具体情况，加强与投资者的互动交流，公司拟召开 2022 年年度报告 业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 11 日（星期四） ...

Financial Performance - Operating revenue for the first quarter of 2023 reached CNY 135,818,714.64, representing a year-on-year growth of 9.93%[11] - Net profit attributable to shareholders for the first quarter was CNY 1,725,600.86, a significant increase of 597.77% compared to a loss of CNY 346,669.28 in the same period last year[11] - The net cash flow from operating activities improved by 131.57%, totaling CNY 44,719,774.44, compared to a negative cash flow of CNY 141,657,077.20 in the previous year[11] - The company's total comprehensive income for Q1 2023 was CNY 402,941.10, down 74.7% from CNY 1,587,375.91 in Q1 2022[70] - The company reported a total revenue from sales of goods and services of CNY 166,495,707.79 in Q1 2023, compared to CNY 164,356,887.67 in Q1 2022, reflecting a growth of 1.3%[71] Assets and Liabilities - Total assets as of March 31, 2023, amounted to CNY 1,250,149,035.87, reflecting a 0.58% increase from the end of the previous year[11] - The total current assets as of March 31, 2023, amounted to CNY 684.90 million, an increase from CNY 675.35 million as of December 31, 2022, representing a growth of approximately 1.83%[56] - The total liabilities as of March 31, 2023, were CNY 237.03 million, slightly up from CNY 231.58 million at the end of 2022, indicating a 2.1% increase[58] - The company's total assets reached CNY 1.25 billion as of March 31, 2023, compared to CNY 1.24 billion at the end of 2022, showing a growth of approximately 0.14%[58] Shareholder and Equity Information - The total number of ordinary shares remained at 128,000,000, with 76.82% held by the controlling shareholder[20] - The total assets held by major shareholders reached 72,168,218, accounting for 56.38% of the company's total equity[24] - The company has committed to measures for stabilizing stock prices, including public explanations and apologies if specific actions are not taken[38] - The controlling shareholder and actual controller pledged not to abuse their positions and to maintain the company's and shareholders' legal rights[46] Research and Development - Research and development expenses increased by 113.28% year-on-year, primarily due to increased outsourcing and project investments[14] - Research and development expenses increased to CNY 4,792,473.34 in Q1 2023, up from CNY 2,247,010.34 in Q1 2022, reflecting a growth of approximately 113%[65] Cash Flow and Investments - Cash flow from operating activities generated a net amount of CNY 44,719,774.44 in Q1 2023, compared to a negative CNY 141,657,077.20 in Q1 2022[71] - Investment activities resulted in a net cash outflow of CNY 13,198,037.42 in Q1 2023, an improvement from a net outflow of CNY 31,311,945.05 in Q1 2022[72] - The company has invested up to 30 million RMB in the Deyan Selected No. 3 Bond Private Securities Investment Fund to improve fund utilization[35] Legal and Compliance Matters - The company is pursuing legal action to recover 257 million from a related party, which is crucial for protecting shareholder interests[28] - The company has successfully completed a series of internal compliance procedures regarding significant transactions and related party dealings[27] - The company is currently involved in a legal case with a total preservation amount of 273,107,940.57 RMB against Jinsanjian Investment Co., Ltd. and Lin Yanhe[29] Future Outlook and Guidance - The company has set a performance guidance of 4,762,507, indicating a 3.72% growth expectation for the next quarter[22] - The controlling shareholder's commitment to increase shareholding has been extended to July 31, 2023, to protect the interests of minority shareholders[52] - The company is actively exploring market expansion opportunities and new product development strategies to enhance growth[24]

Recognition and Market Position - In 2022, the company was recognized as a "Little Giant" enterprise by Yunnan Province, highlighting its specialized and innovative capabilities[3]. - The company was listed among the top 100 Chinese traditional medicine enterprises for 2021, indicating its strong market position[5]. - The company is recognized as a provincial-level "specialized, refined, distinctive, and innovative" enterprise[53]. Product Development and Recommendations - The company's core product, Dengzhanhua Shengmai Capsule, received multiple recommendations in 2022, including from the "Guidelines for the Management of Chronic Diseases in Elderly Patients with Ischemic Stroke" and the "2022 Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack in China"[6][7]. - The company reported a significant increase in its product recommendations, which may enhance its market presence and sales potential[4]. - The company is focused on developing new products and technologies to meet unmet clinical needs, which is crucial for its growth strategy[13]. Financial Performance - The company reported a significant increase in its product recommendations, which may enhance its market presence and sales potential[4]. - The company's operating revenue for 2022 was approximately ¥587.34 million, representing a 3.74% increase from ¥566.17 million in 2021[34]. - The gross profit margin improved to 80.78% in 2022, up from 80.01% in 2021[34]. - The net loss attributable to shareholders was approximately ¥49.17 million in 2022, a significant decline of 158.90% compared to a profit of ¥83.49 million in 2021[34]. - The company experienced a substantial increase in the net loss after deducting non-recurring gains and losses, amounting to approximately ¥77.07 million in 2022, compared to a profit of ¥47.07 million in 2021, marking a 263.74% decrease[34]. - The weighted average return on equity (ROE) based on net profit attributable to shareholders was -4.73% in 2022, down from 8.03% in 2021[34]. - The basic earnings per share (EPS) dropped to -0.40 in 2022, a decrease of 159.70% from 0.67 in 2021[34]. Operational Challenges - The company faced significant risks due to the expansion of centralized drug procurement, which may impact sales and profit margins[12]. - The company is undergoing a relocation of its production base from Kunming to Mile, which poses risks of core technical personnel loss[18]. - The production process is complex, and any quality control issues during the relocation could lead to significant operational disruptions[17]. - The company faces increased comprehensive cost pressures due to rising labor costs and fluctuating prices of traditional Chinese medicine materials[20]. Research and Development - The company is committed to building a high-level R&D team and has established a comprehensive project management system to mitigate innovation risks[13]. - The company focused on enhancing research and development capabilities, collaborating with top universities and research institutions to improve product value and efficiency[56]. - The company has strengthened its intellectual property protection, enhancing its core competitiveness in the Dengzhanhua industry[57]. Market Strategy and Expansion - The company aims to enhance its market strategy by focusing on high-quality evidence-based medical value and expanding into underdeveloped markets, including OTC and digital marketing channels[13]. - The company plans to adapt its business strategies in response to ongoing healthcare reforms and regulatory changes in the pharmaceutical industry[16]. - The company aims to become a leader in the prevention and treatment of ischemic cardiovascular and cerebrovascular diseases, focusing on the entire lifecycle management of high-risk groups[56]. - The company is actively advancing the construction of the Yunnan Biovalley Health Industry Park project, which faced delays but is currently in the equipment installation phase[60]. Financial Management and Risks - As of the financial report approval date, the controlling shareholder, Shenzhen Jinsanjiang Investment Co., Ltd., had not returned a total of 257 million yuan in funds occupied by the company[14]. - The company has initiated legal actions to recover the occupied funds, including sending collection letters and filing civil lawsuits[158]. - The total amount involved in litigation and arbitration is 273,107,940.57 RMB, accounting for 27.00% of the company's net assets[164]. - The company has reported a significant related party transaction involving the occupation of funds by金沙江, which poses risks to operational cash flow and profitability[186]. Shareholder Commitments and Governance - The company has committed to returning occupied funds and is in the process of rectifying this issue, although it has not yet fulfilled this commitment[199]. - The company has committed to distributing no less than 30% of the average distributable profit over the last three years in cash dividends, contingent on meeting the conditions for cash dividend distribution[199]. - The company has established a framework for managing related party transactions, ensuring transparency and accountability in its operations[195]. - The company has fulfilled its commitment regarding the non-transfer of shares for twelve months following the listing on the selected tier, ensuring shareholder confidence[197].

Financial Performance - The company reported a total operating revenue of ¥587,519,585.12, representing a year-on-year increase of 3.77%[4] - The net profit attributable to shareholders was estimated at -¥47,642,140.67, a decline of 157.07% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was projected at -¥79,131,166.88, down 268.11% year-on-year[5] - Basic earnings per share were expected to be -¥0.38, a decrease of 156.72% from the previous year[5] Assets and Equity - Total assets at the end of the reporting period were estimated at ¥1,240,309,977.63, a decrease of 4.50% year-on-year[5] - Shareholders' equity attributable to the company was projected to be ¥1,012,917,645.77, down 4.95% compared to the previous year[5] - The estimated net asset value per share was ¥7.91, reflecting a decline of 5.04% year-on-year[5] Expenses and Challenges - Increased sales expenses were attributed to efforts to stabilize revenue amidst market challenges, including the impact of the pandemic and policy changes[6] - The decline in profit was also influenced by the failure of the controlling shareholder to repay funds on time, leading to an estimated profit reduction of approximately ¥89.95 million[7] Financial Reporting - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the annual report[8]

Financial Performance - The company expects a net loss for the reporting period, estimated between -47.64 million to -58.56 million CNY, compared to a profit of 83.49 million CNY in the same period last year[4]. - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the official annual report[6]. Sales and Expenses - The increase in sales expenses is attributed to the impact of the pandemic, medical insurance payment reforms, and policies on traditional Chinese medicine procurement, leading to a focus on market expansion and stability[5]. Shareholder Communication - The company is actively communicating with its major shareholder regarding the repayment of funds and is assessing credit risk for outstanding debts[5].